PGY2 Emergency Medicine Residency

Mission statement:

The mission of our Emergency Medicine PGY2 Pharmacy Residency is to cultivate highly skilled, knowledgeable, and compassionate clinical pharmacists who excel in the fast-paced and high-acuity environment. Through rigorous training, advanced research, and comprehensive education, we aim to empower our residents to become leaders in the field, capable of providing exceptional patient care and advancing the practice of pharmacy in any emergency department setting.

Our program is dedicated to:

1. High Acuity Care: Providing immersive experiences in diverse emergency settings to develop proficiency in managing critical and complex patient cases with confidence and precision.
2. Research Excellence: Fostering a robust research environment where residents engage in innovative projects that contribute to the advancement of emergency medicine pharmacotherapy and improve patient outcomes.
3. Educational Advancement: Equipping residents with the skills to educate and mentor future healthcare professionals, and promoting lifelong learning and professional development.

Our ultimate goal is to produce well-rounded, adaptable pharmacists who are prepared to meet the dynamic challenges of emergency medicine and who will continuously strive to enhance patient care and safety in any emergency department.

Elective Rotations:

• Mechanical Circulatory Support (2-4 weeks)
• Solid Organ Transplant (1-4 weeks)
• Pediatric Infectious Disease (2-4 weeks)
• Other interests as identified and available (2-4 weeks)

Qualifications:

• Applicants must be citizens or permanent residents of the United States (no Visas are accepted)
• PharmD Degree from an ACPE-accredited College of Pharmacy
• Completion of an ASHP-accredited PGY1 Pharmacy Residency
• Eligible for Illinois licensure
• PhORCAS Application
  • Letter of intent
  • Curriculum Vitae
  • Three Letters of Recommendation
  • College of Pharmacy transcripts
• PGY-2 applicants should submit their application via PhORCAS – application deadline is January 2^nd, 2025
• An interview is required for eligible applicants

Resident Publications:

• Kandil M, Jaber S, Desai D, Nuñez Cruz S, Lomotan N, Ahmad U, Cirone M, Burkins J, McDowell M. MAGraine: Magnesium compated to conventional therapy for treatment of migraines [published online ahead of print, 2020 Sep 14]. Am J Emerg Med. 2020;S0735-6757(20)30827-5. doi:10.1016/j.ajem.2020.09.033.
• McDowell M, Mokszycki R, Greenberg A, Hormese M, Lomotan N, Lyons N. Single-syringe Administration of Diluted Adenosine. Acad Emerg Med. 2020;27(1):61-63. doi:10.1111/acem.13879
• Schwebke T, McDowell M, Piech L, Mokszycki R, et al. Evaluation of Efficacy of Hypertonic Saline and Mannitol in Combination in Patients with a Traumatic Brain Injury. J Neurol Neurocrit Care. 2019: Volume 2(1): 1–4.
• McDowell M, Nitti K, Kulstad E. et al. Clinical Outcomes in Patients Taking Inhaled Loxapine, Haloperidol, or Ziprasidone in the Emergency Department. Clin Neuropharmacol. 2019; 42(2): 23-26. doi:10.1097/WNF.0000000000000325.
• Shah P, McDowell M, Ebisu R, Hanif T, Toerne T. Adjunctive Use of Ketamine for Benzodiazepine-Resistant Severe Alcohol Withdrawal: a Retrospective Evaluation. J Med Toxicol. 2018; 14(3):229-236. doi:10.1007/s13181-018-0662-8.
• Lyons N, Nejak D, Lomotan N, Mokszycki R, Jamieson S, McDowell M, Kulstad E. An alternative for rapid administration of medication and fluids in the emergency setting using a novel device. Am J Emerg Med. 2015; Aug;33(8): 1113.e5-6. doi:10.1016/j.ajem.2015.01.028.

EM PGY2 Preceptors: